Aims: This study aimed to investigate the influence of tightened regulations on new psychoactive substances in patients with disorders related to these drugs in Japan.
current legislation. 9 These drugs are very similar to controlled substances, but their chemical structure has been slightly modified to circumvent drug prohibition laws. They cannot be detected with existing tests, but have similar effects to controlled substances, such as giving a sense of exaltation and euphoria, and can harm the central nervous system, causing dependence and toxic symptoms. Initially, these new addictive substances were sold in stores and on the Internet because there were no clear rules about their sale. They were readily available and also cheaper than controlled substances.
The expanded abuse of these substances was accompanied by a drastic increase in reports about related adverse events in Japan. At the Japan Poison Information Center, the number of NPS-related consultations has dramatically increased since 2011, 10, 11 and there have been reports of people with hallucinations and delusions, disturbances of consciousness, convulsions, and cardiac arrest caused by acute poisoning requiring emergency medical care. 12 In addition to violence and suicidal behavior, reports about car accidents while under the influence of NPS rose at an alarming rate in Japan. 13 These drugs are now formally known as kiken (or dangerous) drugs in Japan.
As a countermeasure, the Japanese Government began to regulate the use of these substances in the mid-2000s. Since then, regulations have been tightened several times, and efforts have been made to take abusers and vendors of these drugs into custody. A comprehensive designation of illegal drug components was introduced in 2013, and the Japanese Pharmaceutical Affairs Act was revised in November 2014 to increase inspections and sale suspension orders for shops, to stop sales of NPS. In July 2015, it was reported that outlets selling these drugs had been completely eradicated in Japan.
As a result of these actions, many people stopped abusing NPS, but some switched to other drugs. As far as we know, there have been no studies examining the types of drugs now used, or the background and history of drug abuse among these users. The aim of this study was therefore to look at the impact of the tightening of regulations on patients with NPS-related disorders in Japan. It 
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| Data source
The Nationwide Mental Hospital Survey on Drug-related Psychiatric
Disorders is the only complete study of patients with substanceinduced mental health problems in Japan. It has been conducted every other year since 1987, using almost the same methodology, to gather information about drug abuse and drug-dependent people in Japan. Various strategies against drug abuse have been developed based on its results. The survey includes all medical facilities with psychiatric wards in Japan and covers any individuals diagnosed with F1 of the ICD-10 ("Mental and behavioral disorders due to psychoactive substance use") at the time of the survey but to whom F10 does not apply (ie, all "patients with substance-induced disorders due to the use of psychoactive substances other than alcohol"), who were treated as an inpatient or outpatient at one of the target sites during the 2 months from September 1 to October 31 in the year of the survey.
The 2016 survey 14 used the same method as in previous years.
All target sites were notified in writing about the aim and method of the survey and were asked to cooperate with the survey and inform their patients about it. As a general rule, patients were only interviewed if they had given verbal consent. A survey request letter, survey information leaflet, and survey form were sent by mail to each target site, and the attending physician was asked to fill out the survey form for patients with substance-induced mental health problems who fulfilled the requirements described above.
The survey items included demographic data (gender, age), highest level of education (high school graduate or higher/less than high school The 2016 survey also included questions on "whether the patient had switched to another drug as primary drug at the time of this survey after using NPS as primary drug in the past." Those to which this applied were asked to select all items that applied about the reason why they had changed to a different drug from: "Because NPS were no longer available," "Because I had personal experience that NPS can cause severe health problems, and therefore did not want to use them anymore," "Because the punishment for use of NPS is now more severe, and I did not want to be put into prison,"
"Because I became afraid of using NPS after hearing, eg, in the news that they can cause severe health problems," and "Others."
Patients who did not want to participate in the survey were reported as "Refused to participate in this survey." If it was difficult to interview patients because of their medical condition or they had already been discharged from hospital, then data were used from their medical records, and it was not considered necessary to obtain consent.
| Subjects
The subjects of this study were anyone who had switched to another drug as their primary drug after using NPS as their primary drug in the past, and had used another drug as their primary drug during the 12 months before the survey. This group is known in this study as the "switch group." The subjects also included a group of participants who used NPS as their primary drug, and had used these drugs during the previous 12 months ("NPS group").
| Procedure
The following points were examined for each individual in the switch group:
1. Drug of abuse (primary drug) at the time of the survey. 
| Statistical analysis
We used Pearson's chi-square test to compare the two groups because we examined only qualitative variables. In a two-sided test, the level of significance was set at less than 5%. Multiple comparisons were required to compare all items related to lifetime experience with each drug between the two groups, so the test had to be repeated 12 times. We therefore used the Bonferroni correction, and the level of significance was set at less than 0.42% (0.05/12 or approximately 0.0042).
| Ethical considerations
The conduct of this investigative study was approved by the ethics committee of the National Center of Neurology and Psychiatry (Approval No. A2016-002). A total of 101 people (4.5%) had used NPS as their main drug, and of these, 25 (1.1%) had used these drugs in the last 12 months and were designated as NPS group.
| RESULTS
In the switch group, the most frequently used primary drug type at the time of the survey was methamphetamine (25 individuals, 35.2%), followed by hypnotics and anxiolytics (11 people, 15.5%), cannabis, volatile solvents, and multiple substances (10 people, 14.1%, each), and commercially available drugs (five people, 7.0%).
The most frequent reason why individuals in the switch group had changed to another primary drug was "Because NPS were no longer available" (38 people, 53.3%), followed by "Others" (17 people, 23.9%), "Because I had personal experience that NPS can cause severe health problems, and therefore did not want to use them anymore" (16 people, 22.5%), "Because the punishment for use of NPS is now more severe, and I did not want to be put into prison" (14 people, 19.7%), and "Because I became afraid of using NPS after hearing, eg, in the news that they can cause severe health problems"
(nine people, 12.7%).
A comparison of the attributes that were examined is shown in 
| DISCUSSION
When NPS were recognized as a serious social problem in Japan, regulations were tightened to reduce their supply. However, the effect of these tightened regulations on abusers of these drugs was unclear. This is the only study of which we are aware that has identified and explored the clinical features of individuals who have switched from NPS to other drugs of abuse as a result of regulations. It has also showed how the tightening of regulations resulted in changes to patients with NPS-related disorders in psychiatric care
by comparing individuals that have abused these drugs in the past but now switched to other drugs of abuse, with individuals who have continued to abuse NPS after regulatory changes.
The 2012 Nationwide Mental Hospital Survey on Drug-related Psychiatric Disorders added items on NPS to help hospitals to cope with the rapid increase in patients with disorders induced by these drugs. NPS were immediately the second-most popular primary drugs of abuse after methamphetamine, which continues to cause major problems in clinical psychiatry in Japan. 15 Patients using NPS as their primary drug and who had used these drugs during the last 12 months accounted for 14.5% of all eligible subjects. In the 2014 survey, NPS again ranked second, and the percentage of patients using these as their primary drug of abuse increased from 16.3% to 23.7%. 16 Patients using these as their primary drug, and who had used them during the previous 12 months accounted for 22.5% of all eligible subjects, and NPS were the most popular drugs used dur- 
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In this study, the switch group had mostly switched from NPS to methamphetamine, followed by hypnotics and anxiolytics, cannabis, and volatile solvents. More than half of the respondents answered that the reason they had changed to a different drug was "Because European countries have responded quickly to NPS by classifying certain substances as medicines. 19, 20 Although products defined as medicines require more rigorous testing and face more regulatory controls on the marketing of any physiological corrective benefits,
classifying an NPS as a medicine would avoid criminalizing its use.
Several NPS have successfully been removed from markets in a handful of European countries. 19, 20 Legal frameworks such as consumer safety and medicine laws appear to be useful in protecting public health without the need for new drug laws with heavy criminal penalties. A blanket ban is likely to minimize, but not eliminate, NPS abuse but increase the prevalence of other substance abuse. 19, 20 This study had several limitations. First, its targets were patients with substance-related disorders who were treated at psychiatric care facilities as an inpatient or outpatient. These patients therefore do not necessarily reflect the characteristics of drug abusers in the community. The second limitation is that the number of subjects was very small so future studies should try to involve more people. The third limitation is that the information used in this study was collected by the attending physician for individuals with substance-related disorders at each trial site. It is possible that the evaluation criteria used by each physician varied, and that in therapeutic settings, patient declarations were biased. The fourth limitation is that to set up an appropriate multivariate analysis model, the target variables used for the analysis were reduced to the requisite minimum. The analysis therefore did not include variables, for example, for comorbid disorders or family background, which might have affected results.
| CONCLUSION
From the mid-2000s, NPS have been a serious social problem in Japan. As a result of regulatory changes, however, the number of patients with disorders relating to these drugs in psychiatric care
sharply decreased. This study showed that a proportion of subjects who had mainly abused NPS in the past had switched to other drugs of abuse, and that about half of these people switched to methamphetamine or cannabis. Compared with individuals who continued to abuse NPS after regulatory changes, many patients who switched from NPS to other drugs had experience of previous use of methamphetamine and had used other drugs before starting to use NPS.
This suggests that these patients might have switched from NPS to illegal drugs such as methamphetamine, or to legal drugs such as prescription drugs, when NPS became less available.
It is important to control access to dangerous drugs by law.
This study, however, shows that when particular drugs are made unavailable, people who suffer from drug addiction will search for and use other drugs instead. Limiting access to one particular type of drug therefore does not solve the problem of drug dependence. Antidrug measures in Japan traditionally interrupted the supply of drugs, but this does not seem to be sufficient. It is also important to ensure that the demand for drugs is reduced, by providing treatment and support systems to prevent drug abuse.
